Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster

Valneva and Pfizer have reported positive data from the Phase II VLA15-221 clinical trial of a second booster dose of their Lyme disease vaccine candidate, VLA15, administered one year after the initial booster.